CSL's flu vaccines rebranded as Seqirus
The newly named business, which means "securing health for all of us," combines the global biotherapeutics leader's existing vaccines and pharmaceutical subsidiary bioCSL with Novartis' flu vaccine business acquired by CSL in July.
Headquartered in the British town of Maidenhead, Seqirus is now the second-largest influenza vaccine company in the world. It has manufacturing plants in the United Kingdom, Germany, Australia and the United States, and operates in more than 20 countries.
“We are excited about the new brand and the future it represents,” CSL CEO and Managing Director Paul Perreault said. “Together, as one business, Seqirus has a diverse product portfolio, extensive sales reach and the appropriate scale of R&D and manufacturing capabilities to leverage and compete globally. With nearly a century of experience in influenza, our expectation is for Seqirus to become a partner in pandemic responses and a major force in the prevention and control of influenza.”
CSL began producing influenza vaccines in 1919 during the Spanish flu pandemic. Seqirus will offer assistance in preparedness for future pandemics.
“The official name change to Seqirus is the next exciting step in our transformation,” Seqirus President Gordon Naylor said. “While we have a new brand, our commitment to continuing a reliable supply of our high-quality products is of paramount importance and will not change.”